New Limb-Girdle Muscular Dystrophies Classification

24 June 2021

This WEBINAR discusses the new classification of LGMDs and maps the current classification to the previous one, explaining the rationale of the updates that were done. It includes therefore a ample discussion of disease causes, mechanisms and ontologies to enable a smoother transition to the new classification system for LGMD sub-types that hopefully is most useful to patients, researchers and clinicians and complies with classification systems established by OMIM (Online Mendelian Inheritance in Man), Orphanet and ICD (International Classification of Diseases)-11.

Read about the patient’s leaflet on the classification here.

Volker Straub is Harold Macmillan Professor of Medicine and Professor of Neuromuscular Genetics, Newcastle University Deputy Dean, director of the Institute of Translational and Clinical Research Newcastle University  and John Walton Muscular Dystrophy Research Centre Honorary Consultant in Clinical Genetics.
He trained as a paediatric neurologist at the University of Dussledorf and the University of Essen, Germany. Following this, he completed his PhD on Duchenne muscular dystrophy and took up a postgraduate post in Kevin Campbell’s laboratory at the University of Iowa, on limb girdle muscular dystrophies (LGMD).
Professor Straub’s interest in muscle diseases is in translational research.
He was the co-founder of the EU FP6 funded network TREAT-NMD, which he coordinated with Professor Kate Bushby. He is a long standing core member of the TREAT-NMD TACT committee, which offers guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases.
His current research involves the application of muscle imaging, the use of zebrafish and mouse models, next generation sequencing and other –omics technologies for the characterization of primary neuromuscular disorders.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern